Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProKidney Corp. - Class A Ordinary Shares (NQ:PROK)

2.245 +0.025 (+1.13%)
Streaming Delayed Price Updated: 2:31 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ProKidney Corp. - Class A Ordinary Shares

< Previous 1 2 Next >
News headline image
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports Full Year 2024 Financial Results and Business Highlights
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in the UBS Virtual Organ Restoration Day
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in the Jefferies Global Healthcare Conference
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
From ProKidney
Via GlobeNewswire
News headline image
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
From ProKidney
Via GlobeNewswire
News headline image
ProKidney to Participate in Jefferies Biotech on the Bay Summit
From ProKidney
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.